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ABSTRACT 
Objective: Buccal drug delivery is the most suited route for local as well as systemic delivery of drugs. Cilnidipine is an L/N type dihydropyridine 4th 
generation calcium channel blocker (CCB), which decreases hypertension by blocking the N-type calcium channel to attenuate vascular sympathetic 
neurotransmission. It has high first-pass metabolism leading to low bioavailability. Hence the present research work was undertaken to formulate 
mucoadhesive buccal film of Cilnidipine with an objective to enhance therapeutic efficacy, bioavailability and was developed to administer into the 
unconscious and less-co-operative patients. 
Methods: Cilnidipine buccal films were prepared by a solvent-casting technique using various concentrations of mucoadhesive-polymers such as 
Hydroxyl propyl methylcellulose (HPMC) E15 and K4M and ethyl-cellulose as backing-layer, which acts like a patch providing unidirectional drug 
release. Prepared films were evaluated for their weight variation, thickness, surface-pH, swelling-index, drug content uniformity, in vitro residence 
time, folding endurance, tensile strength, in vitro release and permeability studies.  
Results: The infra-red (IR) spectra showed no interaction, and Physico-chemical characteristics were found within the limit. Swelling of the film 
increases with increasing concentration of polymers and %drug content of all formulations found to be in the range of 92.13%±0.94% to 
97.92%±0.35%. The formulation F5, showed a promising tensile strength, folding endurance and in vitro drug release of about 95.18±0.03%, thus 
can be selected as an optimized formulation of mucoadhesive buccal film. 
Conclusion: The formulation of Cilnidipine mucoadhesive buccal film was found to be satisfactory and reasonable. 
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INTRODUCTION 
Among the various routes of drug delivery, oral route is the most 
convenient, easily preferred and patient compliance one. However, 
drugs administrated orally undergoes hepatic first-pass metabolism 
and enzymatic degradation in the gastrointestinal tract (GI) or both. 
These are the main reason the oral route is prohibited for the certain 
class of drugs. Transmucosal delivery of drug through various 
mucosal surfaces (nasal, rectal, vaginal, ocular and oral mucosa: 
buccal, sublingual) may be a possible alternative solution over oral 
drug delivery system [1]. In recent year, potential interest has been 
shown in the development of patient compliance formulation for 
better and sustained drug delivery is an integral part of research [2]. 
Among the various trans-mucosal routes, buccal mucosa has unique 
physiological features as an ideal route for mucoadhesive drug 
delivery [3]. Its anatomical and physiological features, like the 
presence of smooth muscles with high vascular perfusion, have 
direct access to the systemic circulation through the internal jugular 
vein, which bypasses the drug from hepatic first-pass metabolism 
and hence can potentially improve the bioavailability [4]. It is the 
most suited route for local as well as systemic drug administration. 
Buccal films have gained importance as efficacious, economic, 
patient-friendly and novel drug delivery systems [5]. 
The drug release and permeation through the buccal mucosa layer 
are affected by the microenvironment of the mucosa. The 
microenvironment of the mucosa may be altered or changed with 
the support of a well-designed mucoadhesive drug delivery system. 
This system designed and developed with the support of 
mucoadhesive polymer which is generally of high molecular weight 
and of high viscosity grades with higher flexibility and optimum 
chain length [6]. The main property of the buccal film, among the 
various mucoadhesive drug delivery, is that due to the large surface 
area of film, it allows quick hydration of film, which accelerated drug 
absorption as compared to buccal tablet and buccal or oral gels, in 
terms of comfort and flexibility [7]. The order of permeability of 
drug molecule through oral cavity is given as 
sublingual>buccal>gingival>palatal [8]. 
Cilnidipine is an L/N type dihydropyridine 4th generation calcium 
channel blocker (CCB), used mainly in the treatment of uncontrolled 
blood pressure and post-stroke hypertensive patients. It is a BCS 
class II drug having low bioavailability of 06-30% due to hepatic 
first-pass metabolism [9]. Hence to improve the therapeutic efficacy 
and bioavailability the drug may be administrated by the buccal 
route through mucoadhesive buccal films. Buccal delivery of 
Cilnidipine may bypass hepatic first-pass metabolism and improve 
bioavailability. Hence the present work deals with the formulation 
and characterization of mucoadhesive buccal film using 
mucoadhesive polymer hydroxyl propyl methylcellulose (HPMC) 
E15, K4M and ethyl cellulose as a backing layer. 
MATERIALS AND METHODS  
Cilnidipine was a gift sample from Pure Chem Pvt. Ltd. Ankleshwar, 
Gujarat. HPMC E5, HPMCE15, HPMC K4M and Ethylcellulose were 
gift samples from Colorcon Pvt. Ltd. Verna, Goa. All other chemicals 
and reagents were analytical and pharmacopeial grade.  
Preformulation studies 
Preliminary trials for selecting suitable polymers and 
plasticizer 
Preliminary trials of formulation development were carried out 
using film-forming polymers such as HPMC E3, E5, E15 and K4M etc. 
HPMC E3 shows thin film formation and E5 films were easily prone 
to breaking and cracking. E15 has good film-forming property, good 
folding endurance and a satisfied appearance. HPMC controlled 
released polymer grade, HPMC K4M show good results in buccal film 
formulation. Propylene glycol was taken 10% w/w of the polymeric 
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concentration, whereas if the concentration of plasticizer was 
altered it leads to poor flexibility at lower concentration and sticky 
appearance at higher concentration. 
Determination of melting point of the drug 
Melting point of Cilnidipine was determined by using the capillary 
tube method using melting point apparatus. 
Fourier transform infrared spectroscopy (FTIR) studies 
Compatibility of Cilnidipine with excipients was confirmed by FTIR 
studies. FTIR study was conducted using the potassium bromide disc 
(pellet) method. The FTIR spectrum of pure drug Cilnidipine and a 
physical mixture of Cilnidipine with film-forming polymer (HPMC E15, 
HPMC K4M), plasticizer (Propylene glycol) and backing layer excipients 
were recorded using FTIR (IR Affinity S1, Shimadzu, Kyoto, Japan).  
Differential scanning calorimetry (DSC) studies 
The DSC thermogram of pure drug was recorded using Differential 
Scanning Calorimetry equipped with a computerized data station. 
Sample was weighed and heated in a closed pierced aluminum pan 
at a heating rate of 10 ᵒC/min between 30 ᵒC and 300 ᵒC and 
nitrogen flow rate 25 ml/min. It provides an idea about the 
interaction of various materials at different temperatures. It also 
allows studying the possible degradation pathways of the materials. 
It gives an idea about the physical and chemical interaction between 
the drugs. 
Determination of absorption maximum (λ max) of the drug 
Stock solution of the drug was prepared using phosphate buffer 
solution (PBS) of pH 6.8 to give a concentration of 100 ppm. 1 ml 
from above solution was diluted up to 10 ml in a volumetric flask to 
give concentration of 10 ppm. Wavelength was scan from 400-200 
nm was done to find the absorbance maxima. 
Method 
Solvent casting technique 
The mucoadhesive buccal film is prepared by solvent casting 
technique; it is one of the simple methods than the other buccal film 
formulation methods and is the most widely accepted 
manufacturing process utilized for the production of films. Solvent 
casting technique has greater clarity and uniformity of thickness 
than extrusion method. In this method, the required quantity of 
polymer dissolved in distilled water. On the other hand, active 
pharmaceutical ingredients (API) and other excipients are dissolved 
in a suitable solvent system. Afterwards both the solutions are 
mixed and stirrer to form homogeneous mixture. This resultant 
solution is called as “casting solution”. The casting solution is poured 
into casting mould and the solvent is evaporated. The method for 
preparation of Cilnidipine of mucoadhesive buccal film and backing 
layer given below as follows: [10] 
Preparation of mucoadhesive buccal film 
Mucoadhesive buccal film of Cilnidipine was prepared by a solvent-
casting technique using a film-forming mucoadhesive polymer as 
per the formula given in table 1. Initially, the polymers HPMC E15, 
HPMC K4M were weighed accurately and dissolved in 2 ml ethanol 
and 3 ml distilled water. The beaker containing polymers, ethanol 
and water was kept aside for 15 min for swelling of polymers. Then 
the polymeric solution stirred for 1h on the magnetic stirrer to get 
the clear and bubbles-free solution. Plasticizer 10% w/w of 
polymeric concentration was added to the polymeric solution with 
continuous stirring. In another beaker Cilnidipine with sodium 
saccharin were dissolved in a sufficient quantity of solvent (Ethanol: 
water 1:1). The solution was continuously stirred for 4 h. Then the 
drug-containing solution and polymeric solution with other 
excipients mixed evenly with the help of a magnetic stirrer to form 
the homogeneous casting solution. The whole solution poured into 
the pre-lubricated glass petri-plate at 40 ᵒC and left for 12 h. The 
film was removed carefully after drying and cut into 2×2 cm². The 
film was stored in butter paper covered with aluminum foil and 
stored at room temperature. 
Preparation of backing layer 
For the preparation of the formulations, a glass petri-plate of 9 cm 
diameter was utilized as a film casting surface. The accurately 
weighed 5% Ethylcellulose (20 cps) was dissolved in the solvent 
mixture isopropyl alcohol: acetone (3:1) and kept for stirring for 4-5 
h. 1% Amaranth solution was used to give color to the backing layer. 
The backing solution was poured slowly to the pre-lubricated glass 
petri-plate and air-dried overnight. The backing layer formed after 
drying was removed carefully and cut in to 3×3 cm² and stored at 
room temperature covered in butter paper wrapped. 
 
Table 1: Composition of mucoadhesive buccal film 
 Formulation ingredients Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Cilnidipine (mg) 158.96 158.96 158.96 158.96 158.96 158.96 158.96 158.96 158.96 
HPMC E15 % 3 3 3 4 4 4 5 5 5 
HPMC K4M % 0.5 1.5 2.5 0.5 1.5 2.5 0.5 1.5 2.5 
Propylene Glycol % 10 10 10 10 10 10 10 10 10 
Sodium saccharin % 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Ethanol/Distilled water (ml) q. s q. s q. s q. s q. s q. s q. s q. s q. s 
 
The amount of drug per batch dose calculation  
Dose of drug per film = 10 mg 
An area of one film = 4 cm² 
Area of petri plate = 63.585 cm² 
Drug to be added per batch
= ( Dose of drug per film × Area of petri plate)
÷ Area of 1 film. 
= (10 × 63.585) ÷ 4 = 158.96 mg. 
Evaluation of cilnidipine mucoadhesive buccal film 
Appearance 
Visual inspection of mucoadhesive buccal films was assessed for 
their appearance of visible imperfections and surface texture of 
films were analyzed by feel or contact [11]. 
Weight variation 
Three films of every 9 films of 2×2 cm² for each formulation were 
weighed individually and calculated. A calibrated electronic 
weighing balance is used for weighing mucoadhesive buccal film. 
The mean weight of all films is calculated [12]. 
Thickness 
A calibrated digital micrometer screw gauge is used to determine 
the thickness of the mucoadhesive buccal film. The thickness of films 
was measured at five different points (four on the corners and one in 
the center) using a digital micrometer screw gauge. The average 
thickness of all films is calculated [13]. 
Folding endurance 
Folding endurance of the films was determined by repeatedly folding 
the small strip of size (2×2 cm²) at the same place till it breaks. The 
number of times the film can be folded at the similar place without 
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breaking give the value of folding endurance. The three readings 
average and standard deviation of all films is calculated [14]. 
Tensile strength 
Mucoadhesive buccal film of size 2×2 cm² was placed between the 
clamp of the stand and clip through which the weighing pan was 
attached above the ground level in the air. For the measurement of 
tensile strength of the film the weights were added to the pan till the 
film breaks. The load causing the deformation and rupture of film 
was calculated by the following equation: [14] 
Tensile strenght
= weight placed on pan along with clip and pan (kg)
/width of film (cm) × thickness of film (cm) 
Unit Kg/cm² 
Multiply Kg/cm² by 0.098 (acceleration due to gravity) to get N/mm². 
Mucoadhesive strength 
The mucoadhesive strength is determined by an analytical balance. 
Mucoadhesive buccal film is placed on the glass slide by placing a drop of 
water on slide on the one side of analytical balance another end 
weighing pan was attached. Weight was slowly added to the pan until 
glass slide get detached from film. Weight required to detach the film 
from the glass slide is measured as mucoadhesive strength. The 
mucoadhesive strength of each formulation (n=3) was calculated [14]. 
Surface pH 
For determining the surface pH of mucoadhesive buccal film, three 
buccal films of each formulation were allowed to swell for 15 min at 
room temperature in the contact of 1 ml distilled water (pH 6.6±0.5), and 
the pH was determined by bringing the electrode in contact of buccal 
film surface and allowing equilibrate for 1 min [15]. The surface pH was 
recorded using pH meter (Toshcon industries Pvt. Ltd.). 
Drug content uniformity 
Film of dimension 2×2 cm² was added in 100 ml of phosphate buffer pH 
6.8, stirred continuously in benchtop orbital shaker for 24h. Additionally, 
this solution was filtered, suitably dilution, and analyzed at 240 nm using 
a UV spectrophotometer. The average and standard deviation of drug 
content for three films was taken as final reading [16]. 
Swelling index 
Swelling index was determined by positioning the buccal film of size 
2×2 cm² pre-weighed on wire mesh placed into a clean petri plate 
filled with 15 ml of phosphate buffer pH 6.8. Buccal film weight was 
measured at the regular interval till it remained constant and an 
average of 3 films was taken. Swelling index (SI) was calculated by 
using the following formula [17]. 
Swelling index (SI) = (W − Wo)/WO 
Where;  
SI = Swelling index 
W = Final weight of buccal film 
Wo = Initial weight of buccal film. 
Percentage moisture uptake 
In order to evaluate the films of dimension 2×2 cm² were weighed 
and accurately placed in the desiccator at room temperature for 
3days with saturated ammonium chloride solution and maintained 
79.5% Relative Humidity. The films were taken out and weighed 
after 3days. Percentage of moisture uptake was calculated using the 
following formula [18]. 
Percentage moisture uptake = [
Final weight − Initial weight
Final weight
] ×  100 
Percentage moisture loss test 
In an evaluation of percent moisture loss, the accurately weighed 
film was placed in the desiccator containing calcium chloride (fused 
anhydrous) for 3 d. After 3 d the film was reweighed, percentage 
moisture loss was calculated by the following formula [18]. 
Percentage moisture loss = [
Initial weight − Final weight
Initial weight
] ×  100 
Residence time 
Residence time of film was obtained on goat mucosal surface. A film 
of dimension 2×2 cm² was placed on outer layer of mucosa, and both 
the layer were put into the petri plate filled with 5 ml of PBS pH 6.8. 
After that the petri plate was placed in benchtop orbital shaker at 50 
rpm at 37 ᵒC. Residence time is determined by the time at which 
buccal film disintegrates on buccal mucosa [19]. 
In vitro drug release 
For in vitro drug release study USP type I apparatus (Basket type) 
dissolution test apparatus containing 250 ml of PBS of pH 6.8 as a 
dissolution medium at 37±0.5 °C temperature and speed at 50rpm. 5 
ml of sample solution was withdrawn at time intervals of 15 min, 30 
min, 45 min, 1h, 2h, 4h, 6h, 8h, 12h, and 24h and equilibrated with a 
new or fresh dissolution medium to maintain sink state. Drug 
release was analyzed spectrophotometrically at a λmax of 240 nm 
using UV-visible spectroscopy (Shimadzu, UV-1800) [20]. 
In vitro diffusion studies 
An in vitro diffusion study was performed by using Franz diffusion cell 
assembly. It consists of two compartments, one of the receptor chambers 
containing a PBS of pH 6.8 and another donor compartment containing 
mucoadhesive buccal film (patch) of 10 mg of the drug. A dialysis 
membrane (molecular size 12000-14000 was previously soaked for 24 
h. Dialysis membrane was placed in contact of PBS filled in receptor 
compartment to avoid disruption in the ongoing process; it was ensured 
that no air bubbles were seen between the dialysis membrane and liquid 
surface of PBS. The temperature was maintained at 37±0.5° Cat 50rpm 
using a magnetic stirrer. 0.5 ml of the sample was withdrawn from the 
receptor chamber side tube at the time interval of 15 min, 30 min, 45 
min, 1h, 2h, 4h, 6h, 8h, 12h, and 24h and equilibrated with a new or fresh 
dissolution medium to maintain sink state. Suitable dilution was carried 
out and was spectroscopically analyzed at a λmax of 240 nm using UV-
visible spectroscopy (Shimadzu, UV-1800) [20].  
Ex vivo permeation studies 
The ex-vivo permeation studies were carried out using a modified Franz 
diffusion cell. The mucoadhesive buccal film of Cilnidipine through an 
excised layer of goat buccal mucosa (washed in isotonic phosphate 
buffer (pH 6.6) after excised and trimming from the sides) was obtained 
from local slaughterhouse. The receptor compartment of Franz diffusion 
cell containing phosphate buffer of pH 7.4 (20 ml) medium and mini 
magnetic bead was placed in receptor compartment. A mucoadhesive 
buccal film of the dimension of 2×2 cm² optimized batch was placed over 
the goat buccal mucosal membrane fitted between the donor and 
receptor compartment. The whole assembly was placed on a magnetic 
stirrer; the temperature was maintained at 37±0.5 °C at 50 rpm. 0.5 ml of 
the sample was withdrawn from the receptor compartment side chain 
and replace with fresh medium at a regular time interval of 15 min, 30 
min, 45 min, 1h, 2h, 4h, 6h, 8h, 12h, and 24h. Suitable dilution was 
carried out and was spectroscopically analyzed at a λmax of 240 nm 
using UV-visible spectroscopy (Shimadzu, UV-1800) to determine the 
amount of drug permeated [21]. 
Stability studies 
A stability study of optimized formulation was executed as per ICH 
guidelines. The single film of dimension 2×2 cm² was wrapped 
individually in butter paper followed by packing in aluminum foil and 
maintained at room temperature 25±2 ᵒC and 60±5% RH and placed in 
accelerated stability condition at 40±2 ᵒC and 75±5% RH for the period 
of 3 months. Changes in appearance, folding endurance, tensile strength, 
drug content, % drug release of the stored mucoadhesive buccal film 
(patch) were analyzed at a regular interval for 3 months [22]. 
RESULTS AND DISCUSSION 
Determination of melting point of the drug 
Melting point of Cilnidipine was found to be in the range of 108-110 
ᵒC and it complies with the IP standard, thus indicating the purity of 
the sample. 
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Drug excipient compatibility studies by FTIR 
IR spectrum of Cilnidipine (drug), physical mixture with excipients 
and backing layer also was recorded and it was found in accordance 
with the reported peaks. There are no observed significant peak 
shifts and no generation of a new peak, although there might be no 
possible interaction between drug and excipients of buccal film. 
FTIR spectra were found to be pure, stable and unaltered [23]. 
 
 
Fig. 1: IR spectrum of pure cilnidipine 
 
 
Fig. 2: IR spectrum of Cilnidipine and polymers (HPMC E15 and HPMC K4M) 
 
 
Fig. 3: IR spectrum of cilnidipine and plasticizer (Propylene glycol) 
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Fig. 4: IR spectrum of cilnidipine and backing layer (Ethyl cellulose, Acetone, Isopropyl alcohol) 
 
 
 Fig. 5: DSC thermogram of cilnidipine 
  
 
Fig. 6: UV spectrum of cilnidipine 
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Table 2: Infrared spectral assignment for cilnidipine 
S. 
No. 




Frequency of drug 
and polymer (cm-1) 
Frequency of drug 
and plasticizer (cm-1) 
Frequency of drug and 
backing layer (cm-1) 
1. C-N Aromatic 2° 
amine (S) 
1020-1250 1197.79 1132.21 1197.79 1111.00 
2. N-O (S) 1360-1550 1344.38 1386.82 1344.38 1363.67 
3. C=O(S) 1630-1980 1693.50 1691.57 1695.43 1708.93 
4. -OCH3 2815-2950 2935.66 2924.09 2927.94 2883.58 
5. C-O (S) 1200-1225 1261.45 1284.59 1263.37 1220.94 
6. N-H Aromatic 2° 
amine (S) 
3250-3400 3282.84 3304.06 3284.77 8396.64 




(a)     (b)     (c) 
Fig. 7: (a) optimized formulation (F5) of Mucoadhesive buccal film. (b) Backing layer. (c) Buccal patch containing mucoadhesive buccal 
film with backing layer 
 
DSC thermogram of drug 
The DSC analysis of the drug was performed. The melting point of 
Cilnidipine was determined, exhibiting a sharp endothermic peak at 
109.6 ᵒC (fig. 5) (Reported value: 108 ᵒ-110 ᵒC) within the reported 
range, which confirms the melting point and thereby the purity of 
drugs [23]. 
Determination of λ max 
A concentration of 10μg/ml was prepared from a standard 
Cilnidipine solution scanned by a UV-visible spectrometer in the 
range of 200-400 nm using 6.8 PBS as blank then the maximum 
wavelength (λ max) was determined (fig. 6). 
Preparation and physical characterization of cilnidipine 
mucoadhesive buccal film 
Preliminary feasibility trials were prepared with different polymers 
like HPMC (E3, E5, E15 and K4M) and plasticizer propylene glycol. 
Finally, from the trails made and results obtained, HPMC (E15, K4M) 
and plasticizer propylene glycol were selected with different levels 
for further formulation development [24]. 
Evaluation of prepared mucoadhesive buccal films 
Appearance 
The physical appearance and flexibility were noted visually, for all 
the films from F1 to F9 were creamish yellow in color, smooth, 
homogeneity and elegant in appearance [25]. 
Weight variation 
The weight of mucoadhesive buccal film was determined using 
digital weighing balance and the average weight of all film (F1 to F9) 
was found to be in the range of 58-81 mg. From the result, it was 
observed that the weight of films increases with the increased in the 
polymer concentration ratio. The drug-loaded buccal film patches 
were found to be uniform [26]. 
Thickness of films 
The average thickness of all the films ranges from 0.0754±0.002 to 
0.165±0.001 mm. F1 shows the lowest thickness and F9 shows the 
highest thickness value. All the film shows a low standard deviation 
that may be due to good positioning during the solvent evaporation 
process. The measured thickness of F1-F9 films was approximately 
less than 1 mm which implies their usefulness for buccal application 
with least discomfort to the patients [27]. 
Folding endurance  
The average folding endurance value of all the mucoadhesive buccal 
films ranges from 126±1 to 215±3. The values were optimum to 
reveal good buccal film properties. Formulation F1 shows the 
highest folding endurance value and F9 shows the lowest folding 
endurance value [28]. 
Mucoadhesive strength  
The mucoadhesive strength values ranged from 4.5±0.5 to 8.4±0.2. 
Formulation F1 shows the lowest mucoadhesive strength value and 
F9 shows the highest mucoadhesive strength value. The present of 
hydrophilic group in polymer bind to mucin through hydrogen 
bond; leading to increase in mucoadhesive strength interaction. The 
Formulation F1 and F2 have lowest polymer concentration; thus, 
have lowest mucoadhesion. The formulation F9 shows highest 
mucoadhesive strength; as the attached buccal film can make the 
removal difficult from buccal cavity, which may cause discomfort to 
patient [29]. 
Swelling index 
Swelling index of all formulations was evaluated. The swelling index 
values of the film ranges from 19.99±1.04 to 35.23±3.43. The 
formulation F1 showed the lowest swelling index and formulation 
F9 showed the highest swelling index. Swelling increases with the 
increase in HPMC concentration due to the presence of more 
hydroxyl group [29]. 
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Surface-pH 
The surface-pH was noted by pH meter near the surface of 
mucoadhesive buccal film and allowed for equilibration and the 
surface-pH of all film was found to be in the range of 6.67 to 6.73 pH 
(n=3). All the formulation batches show pH in neutral range, which 
indicates for the absences of buccal irritation [30]. 
Drug content  
The percent of drug content for all the formulations F1 to F9 was 
obtained in the range of 92.13%±0.94% to 97.92%±0.35%. The 
results indicate that the drug is distributed uniformly in all film 
formulations and will deliver the dose of drug accurately [30]. 
Percent moisture absorption 
The percentage moisture uptake is referred to the function of the 
excipient to absorb the moisture in the form of water vapors. The 
percent moisture absorption of all formulations from F1 to F9 was 
estimated. The average % moisture absorption was found in the 
range of 1.59±0.29% to 3.28±0.15%. All formulation shows moisture 
absorption within limits that is evidence for the physical stability of 
the film in humid conditions [31]. 
Percent moisture loss 
The percent moisture loss of all formulations from F1 to F9 was 
estimated. The average % moisture loss was found in the range of 
1.03±0.05% to 2.32±0.22%. All formulation shows moisture loss 
within limits that is evidence for the stability of the film against 
microbial growth [31]. 
Tensile strength 
Tensile strength of prepared buccal film varies from 3.09±0.12 to 
21.25±0.42 N/mm² revealing that the films had good mechanical 
strength and flexibility. Tensile strength of buccal film increases 
with the increase in the polymeric concentration. Formulation F1 
showed the lowest tensile strength, whereas formulation F9 showed 
the highest tensile strength [32].  
In vitro residence time 
The in vitro-residence time of all formulations from F1 to F9 was 
evaluated of film ranges from 1.85±0.03 to 4.70±0.31. The in vitro 
residence time of all the films were found to be optimum and 
therefore, films exhibited good swelling and drug release 
properties [33]. 
 









Surface pH Drug content 
(%) 
F1 58.73±0.63 0.0754±0.002 215.66±2.08 4.5±0.5 6.67±0.01 94.40%±0.62 
F2 64.61±0.54 0.119±0.001 190.66±2.08 4.30±0.09 6.67±0.02 93.16%±0.62 
F3 73.66±0.57 0.135±0.001 181.66±1.52 5.33±0.57 6.62±0.01 94.82%±1.56 
F4 66.2±0.88 0.125±0.001 163.66±2.51 4.8±0.26 6.65±0.01 93.16%±0.62 
F5 69.87±0.45 0.126±0.005 177.66±3.05 5.66±0.15 6.66±0.01 97.92%±0.35 
F6 78.61±0.60 0.149±0.001 151.66±1.52 6.2±0.2 6.65±0.01 95.65%±1.24 
F7 70.56±0.51 0.134±0.001 183.66±2.08 6.5±0.1 6.70±0.01 93.99%±0.35 
F8 77.33±0.57 0.154±0.001 156.66±2.08 6.8±0.1 6.62±0.04 92.13%±0.94 
F9 80.63±0.55 0.165±0.001 126.33±0.57 8.4±0.2 6.73±0.01 93.37%±0.35 
All data are given in mean±SD 
 











In vitro residence 
time (h) 
F1 2.74±0.11 2.32±0.22 3.09±0.12 19.99±1.04 1.85±0.03 
F2 3.22±0.04 2.04±0.02 5.06±0.17 25.41±0.79 2.06±0.04 
F3 3.28±0.15 2.28±0.12 10.08±0.40 30.18±0.33 2.81±0.06 
F4 2.18±0.31 1.44±0.02 7.39±0.41 32.63±0.38 3.07±0.05 
F5 1.59±0.29 1.55±0.03 14.09±0.71 22.18±0.97 3.92±0.06 
F6 1.69±0.42 1.53±0.01 16.22±0.39 23.13±0.03 4.02±0.02 
F7 1.76±0.61 1.33±0.08 17.06±0.61 31.01±1.44 4.15±0.04 
F8 2.00±0.40 1.46±0.01 19.09±0.44 26.23±0.40 4.32±0.07 
F9 1.72±0.37 1.03±0.05 21.25±0.42 35.23±3.43 4.70±0.31 
All data are given in mean±SD 
 
Table 5: In vitro drug release of cilnidipine mucoadhesive buccal film 
 Time duration Cumulative % drug release 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
15 min 1.89±0.02 3.08±0.05 1.33±0.02 3.40±0.02 4.70±0.02 2.37±0.05 2.38±0.08 2.38±0.04 2.98±0.02 
30 min 4.62±0.08 6.73±0.05 4.82±0.04 7.69±0.06 9.49±0 7.015±0.06 4.87±0.09 6.10±0.14 7.16±0.81 
45 min 10.45±0.07 11.94±0.08 10.91±0.03 13.29±0.08 15.47±0.02 12.42±0.06 10.32±0.10 11.68±0.12 12.60±0.78 
1h 18.54±0.06 20.35±0.02 19.16±0.05 21.62±0.13 23.74±0.02 20.74±0.05 18.32±0.11 19.68±0.09 20.17±0.74 
2h 27.59±0.03 29.24±0.03 28.03±0.15 30.43±0.15 33.00±0.17 29.56±0.11 26.97±0.17 34.14±9.92 28.95±0.66 
4h 38.36±0.11 38.62±0.09 38.71±0.11 39.64±0.13 43.95±0.11 39.25±0.22 37.77±0.16 39.17±0.05 39.40±0.59 
6h 49.89±0.04 49.50±0.05 49.53±0.13 50.54±0.13 55.32±0.06 50.61±0.25 48.53±0.13 50.08±0.09 50.21±0.59 
8h 63.69±0.03 63.16±0.04 63.09±0.13 63.77±0.19 67.97±0.10 63.51±0.23 61.96±0.11 62.89±0.13 61.75±0.63 
12h 78.04±0.02 76.98±0.12 77.18±0.17 77.23±0.15 81.21±0.06 77.06±0.21 75.72±0.16 76.06±0.20 75.18±0.60 
24h 92.73±0.08 91.45±0.12 91.32±0.18 91.40±0.12 95.18±0.03 91.04±0.22 90.33±0.19 90.16±0.23 89.31±0.57 
All data are given in mean±SD 
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Fig. 8: In vitro drug release profile of cilnidipine mucoadhesive buccal film 
 
In vitro drug release  
In vitro dissolution of Cilnidipine mucoadhesive buccal film 
investigation was carried out in pH 6.8 PBS. Drug release from F1 to 
F9 was found to be ranges of 89.31±0.57 % to 95.18±0.03%. It was 
observed that the drug release slower with increasing polymer 
concentration. The formulation F5 was selected as an optimized 
formulation based on these in vitro release studies which showed 
satisfactory drug release rate 95.18±0.03% in 24 h. The selected 
optimized formulation F5 was used further for the evaluation of ex-
vivo permeation studies through goat buccal mucosa [34]. 
In vitro diffusion studies 
In vitro diffusion of all formulations ranges from 76.63±0.30% to 
82.64±0.30%. In the case of F series formulations, F1, initially, the drug 
release was rapid, more than 60% in 2 h and followed by slow release 
and showed about 79.73±0.17% in 24 h respectively. The formulation 
F4 and F5 had shown 57.28±0.173%and 62.59±0.173% in 4 h. There 
appeared no remarkable difference in the final percentage of drug 
diffusion, which might be due to fact that in all formulations, the drug 
dissolved completely in the medium. It is clear from the plots the drug 
diffusion was governed by the polymer content. 
No lag time was observed as the buccal film was directly exposed to 
the medium. An increase in the polymer content was associated with 
decrease in release rate of the drug. Since increasing the amount of 
polymer in the buccal film forms a water-swollen gel-like state that 
could considerably reduce the penetration of medium into the 
buccal film then the drug release was retarded.  
The formulation F5 was selected as an optimized formulation based 
on the in vitro diffusion studies which showed a satisfactory 
diffusion rate 82.64±0.30% in 24 h. The selected optimized 
formulation F5 was used further for the evaluation of ex-vivo 
permeation studies through goat buccal mucosa [35]. 
 
 
Fig. 9: In vitro diffusion profile of cilnidipine mucoadhesive buccal film 
 
Ex-vivo permeation studies 
The formulation F5 was selected as optimum for the ex-vivo 
permeation studies due to adequate in vitro drug release, in vitro 
diffusion and mucoadhesive studies. The result of drug permeation 
from the mucoadhesive buccal film containing backing layer acting 
as a patch providing unidirectional drug release of Cilnidipine 
through the goat buccal mucosa reveals that drug was released 
from formulation and permeated through the goat buccal 
membrane and hence can feasibly be permeated through the 
human buccal membrane. The result indicated that the drug 
permeation was slow and steady and 76.34±0.17% of Cilnidipine 
permeate through the buccal membrane from the optimized 
formulation in 24 h [36]. The cumulative percentage amount of 
Cilnidipine that had penetrated through the buccal epithelium 
from the buccal film was shown in the fig. 10. 
Stability studies 
Based on the above result, stability studies were conducted only for 
optimized formulation F5. Form the stability studies, it was known 
that optimized formulation F5 had stability in human saliva; there 
was no change in the color and integrity of the buccal film. The 
optimized formulation F5 was selected for short term stability 
studies at temperature 25±2 ᵒC and 60±5% RH and accelerated 
stability studies were carried out at 40±2 ᵒC and 75±5% RH for the 
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period of 3months. The buccal film patches were analyzed for 
folding endurance, tensile strength, drug content and in vitro drug 
release. There was a minor decrease in all the parameters [37]. 
Hence the formulation F5 was indicated stable. 
 
 
Fig. 10: Ex-vivo permeation of cilnidipine mucoadhesive buccal film (buccal patch) 
 
Table 6: Short term and accelerated stability studies of optimized batch F5 
Time 
(d) 















In vitro drug 
release 
0 177.66±3.05 14.09±0.71 97.92±0.35 95.18±0.03 177.66±3.05 14.09±0.71 97.92±0.35 95.18±0.03 
30 174.33±1.52 13.97±0.52 97.51±0.62 95.13±0.05 169.66±1.52 13.88±0.65 97.30±0.94 95.11±0.07 
60 169±1 13.61±0.24 97.30±0.35 95.07±0.03 166.33±0.57 13.56±0.70 97.10±0.94 95.01±0.05 
90 166.33±1.52 13.42±0.44 97.10±0.35 95.02±0.07 163.66±0.57 13.34±0.70 96.89±0.62 94.96±0.09 
All data are given in mean±SD 
 
CONCLUSION 
Buccal delivery is an appealing alternative route for the administration 
of drugs that has low bioavailability because of extensive first-pass 
metabolism. The following conclusion could be drawn from the 
various experiments. FTIR studies concluded that there was no drug 
and excipients interaction. The mucoadhesive buccal film containing 
backing layer, which acts like a patch providing unidirectional drug 
release of Cilnidipine, could be prepared by the solvent casting 
technique with mucoadhesive polymers like HPMC E15 and HPMC 
K4M. The prepared films were smooth, flexible and elegant in 
appearance with uniform in weight, thickness, drug content uniformity 
and showing good folding endurance. The physicochemical properties 
of all formulations were shown to be within limits. The surface pH of 
all formulations was in an acceptable salivary pH (5.8 to 7.4). Among 
that formulation, F5 shows better drug release, mucoadhesive 
properties, drug content, tensile strength and accelerated stability 
conditions were found to be stable at specified by ICH. So that F5 batch 
considered as optimized formulation. Ex-vivo permeation studies for 
optimized batch were conducted and shown satisfactory drug 
permeation. Cilnidipine could permeate through goat buccal 
membrane as evidenced from the ex-vivo permeation studies. Hence, 
present study concludes that the Cilnidipine could be delivered 
through the buccal route. 
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